Novo Nordisk Outlines Likely COVID-19 Crisis Trial Impacts
Group Heralds Semaglutide’s Positive Phase II NASH Outcome
Executive Summary
Novo Nordisk said late stage clinical trials near completion would not be hit by the pandemic but that delays to other stage studies were likely, and new ones were now “on hold.”
You may also be interested in...
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Year Of NASH Upheaval Means Incremental Data At AASLD
With still no approved therapy for non-alcoholic steatohepatitis, Intercept, Madrigal, Inventiva and others used the liver meeting to build the cases for their NASH candidates.